Elevated morbidity long-lasting for childhood cancer survivors

This article originally appeared here.
Elevated Morbidity Lasts for Childhood Cancer Survivors
Elevated Morbidity Lasts for Childhood Cancer Survivors

(HealthDay News) -- By age 50 years, more than half of childhood cancer survivors have experienced a severe, disabling, life-threatening, or fatal health condition, according to a study published online March 17 in the Journal of Clinical Oncology.

Gregory T. Armstrong, M.D., from the St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues examined health risks across the aging spectrum for 14,359 five-year survivors from the Childhood Cancer Survivor Study, who were diagnosed before age 21 years and were followed for a median of 24.5 years, and 4,301 of their siblings. At the last follow-up, 5,604 of the survivors were at least 35 years old.

The researchers found that, by age 50 years, survivors had an increased cumulative incidence of a severe, disabling, life-threatening, or fatal health condition, compared with their siblings (53.6 versus 19.8 percent). The hazard ratios (HRs) were significantly increased for survivors versus siblings within age groups: 5 to 19 years (HR, 6.8); 20 to 34 years (HR, 3.8); and 35 years or older (HR, 5.0). Compared with 6.0 percent of siblings, 25.9 percent of survivors who reached age 35 years without a previous grade 3 or 4 condition experienced a subsequent grade 3 to 5 condition within 10 years (P < 0.001).

"Elevated risk for morbidity and mortality among survivors increases further beyond the fourth decade of life, which affects the future clinical demands of this population relative to ongoing surveillance and interventions," the authors write.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs